Cargando…

Efficacy and safety of Molnupiravir in COVID-19 patients: a systematic review

BACKGROUND: Molnupiravir is an oral antiviral drug that received Emergency Use Authorization in three countries for the treatment of mild COVID-19. The aim of this systematic review was to find out the safety and efficacy of Molnupiravir in SARS-COV-2 infections. METHODS: The electronic databases su...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mali, Kalpana Ramanna, Eerike, Madhavi, Raj, Gerard Marshall, Bisoi, Debasis, Priyadarshini, Rekha, Ravi, Gandham, Chaliserry, Leo Francis, Janti, Siddharam S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463664/ https://www.ncbi.nlm.nih.gov/pubmed/36087236 http://dx.doi.org/10.1007/s11845-022-03139-y

Ejemplares similares

Adverse events following remdesivir administration in moderately ill COVID-19 patients - A retrospective analysis
por: Gandham, Ravi, et al.
Publicado: (2022)

Anti-spike Antibody Status in Pre-vaccinated Healthy Participants and Rheumatoid Arthritis Patients During the Third Wave of COVID-19
por: Eerike, Madhavi, et al.
Publicado: (2023)

Everything real about unreal artificial intelligence in diabetic retinopathy and in ocular pathologies
por: Morya, Arvind Kumar, et al.
Publicado: (2022)

Face Mask in COVID-19 and Its Association With Dry Eye Disease: A Cross-Sectional Study
por: Motwani, Rohini, et al.
Publicado: (2022)

Efficacy and safety of molnupiravir for COVID-19 patients
por: Fatima, Maurish, et al.
Publicado: (2022)

Commentary: Intraocular lens formulas for near perfect visual acuity – Search continues
por: Morya, Arvind K, et al.
Publicado: (2021)

Commentary: Importance of ocular and systemic examination among state bus drivers
por: Morya, Arvind K, et al.
Publicado: (2021)

Commentary: Telerehabilitation in ophthalmic practices, a new normal and a must
por: Morya, Arvind K, et al.
Publicado: (2022)

Commentary: Screening the future generation: A path to better future
por: Morya, Arvind K, et al.
Publicado: (2022)

Efficacy and Safety of Molnupiravir in Mild COVID-19 Patients in India
por: Sinha, Shubhadeep, et al.
Publicado: (2022)

Efficacy and safety of baricitinib and tocilizumab in hospitalized patients with COVID-19: A comparison using systematic review and meta-analysis
por: Cherian, Jerin Jose, et al.
Publicado: (2022)

Molnupiravir; molecular and functional descriptors of mitochondrial safety
por: Wallace, K.B., et al.
Publicado: (2022)

Antiviral Efficacy of Molnupiravir for COVID-19 Treatment
por: Bai, Yuan, et al.
Publicado: (2022)

Molnupiravir: First Approval
por: Syed, Yahiya Y.
Publicado: (2022)

Computational Analysis of Molnupiravir
por: Sharov, Artem V., et al.
Publicado: (2022)

Molnupiravir for COVID-19
Publicado: (2022)

Antiviral Efficacy and Safety of Molnupiravir Against Omicron Variant Infection: A Randomized Controlled Clinical Trial
por: Zou, Rongrong, et al.
Publicado: (2022)

Safety and efficacy of molnupiravir in SARS‐CoV‐2‐infected patients: A real‐life experience
por: De Vito, Andrea, et al.
Publicado: (2022)

In vitro and in vivo efficacy of Molnupiravir against Zika virus infections
por: Wang, Zhuang, et al.
Publicado: (2023)

Efficacy of Sotrovimab (SOT), Molnupiravir (MOL), and Nirmatrelvir/Ritponavir (N/R) and Tolerability of Molnupiravir in Outpatients at High Risk for Severe COVID-19
por: Kauer, Victoria, et al.
Publicado: (2023)

Efficacy and safety of molnupiravir for the treatment of SARS-CoV-2 infection: a systematic review and meta-analysis
por: Malin, Jakob J, et al.
Publicado: (2023)

Efficacy and Safety of Molnupiravir Treatment for COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Tian, Fangyuan, et al.
Publicado: (2023)

Molnupiravir efficacy among immunocompromised patients with COVID-19: no proof of concept
por: Guermazi, Dorra, et al.
Publicado: (2023)

Genetic polymorphisms of multidrug and toxin extrusion proteins (MATE1 and MATE2) in South Indian population
por: Raj, Gerard Marshall, et al.
Publicado: (2017)

Narrowband UV-B phototherapy in childhood atopic dermatitis: efficacy and safety
por: Dayal, Surabhi, et al.
Publicado: (2017)

Molnupiravir and Nirmatrelvir/Ritonavir: Tolerability, Safety, and Adherence in a Retrospective Cohort Study
por: Mazzitelli, Maria, et al.
Publicado: (2023)

Safety and efficiency of molnupiravir for COVID-19 patients with advanced chronic kidney disease
por: Dufour, Inès, et al.
Publicado: (2023)

A clinical trial on phakic intraocular lens for the treatment of refractive amblyopia in children and adolescents
por: Morya, Arvind Kumar, et al.
Publicado: (2023)

Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis
por: Wen, Wen, et al.
Publicado: (2022)

Efficacy and safety of molnupiravir in patients with Omicron variant vaccine breakthrough COVID-19 infection: a randomized, controlled trial
por: Liu, Yayun, et al.
Publicado: (2023)

Publisher Correction: Molnupiravir: coding for catastrophe
por: Malone, Brandon, et al.
Publicado: (2021)

Molnupiravir, une affaire franco-européenne
por: Manus, Jean-Marie
Publicado: (2021)

Molnupiravir: From Hope to Epic Fail?
por: Focosi, Daniele
Publicado: (2022)

Why Molnupiravir Fails in Hospitalized Patients
por: Brown, Ashley N., et al.
Publicado: (2022)

Efficacy of Molnupiravir for the Treatment of Mild or Moderate COVID-19 in Adults: A Meta-Analysis
por: Benaicha, Karima, et al.
Publicado: (2023)

Concise two-step chemical synthesis of molnupiravir
por: Pereira, Vinícius R. D., et al.
Publicado: (2022)

Safety Profile of Molnupiravir in the Treatment of COVID-19: A Descriptive Study Based on FAERS Data
por: Santi Laurini, Greta, et al.
Publicado: (2022)

Comparison of the acceptability and safety of molnupiravir in COVID-19 patients aged over and under 80 years
por: Fujita, Kohei, et al.
Publicado: (2023)

Assessment of pharmacokinetics, safety, and tolerability following twice‐daily administration of molnupiravir for 10 days in healthy participants
por: Iwamoto, Marian, et al.
Publicado: (2023)

525. Comparison of the acceptability and safety of molnupiravir in COVID-19 patients aged over and under 80 years
por: Fujita, Kohei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_p2hvol55kp4kibpurfo1c54au8